US Vaccines Market

The report "US Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Forecast to 2029", US vaccines market (excluding COVID-19 vaccines) is projected to reach USD 38.44 Billion by 2029 from USD 25.98 Billion in 2024, at a CAGR of 8.2% during the forecast period. The growth in the US vaccines market is fueled by various factors such as launch of RSV vaccines, increasing investments by government and non-government organizations for vaccine development and increasing R&D investments by market players.

Browse 151 market data tables and 57 figures and in-depth TOC on “US Vaccines Market - Forecast to 2029."
Early buyers will receive 10% customization on reports.

To know about the assumptions considered for the study download the pdf brochure

The conjugate vaccine segment is expected to have the dominant share of the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on technology, the US vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. In 2023, conjugate vaccine segment dominated the US vaccine market. Rising awareness and preventive healthcare initiatives, increasing pediatric immunization programs, and favorable government & regulatory environments have further bolstered the prominence of conjugated vaccines.

The HPV segment is expected to account for the largest share of the disease indication segment in the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on disease indication, the US vaccines market (excluding COVID-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV and other disease indications. RSV vaccine segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Growing investments in vaccine R&D and novel technologies coupled with high disease burden among infants and older adults has fueled demand for RSV vaccines.

The multivalent vaccines segment is expected to account for the largest share of the type segment in the US vaccines market (excluding COVID-19 vaccines) in 2023.

Based on type, the US vaccines market (excluding COVID-19 vaccines) is segmented into monovalent and multivalent vaccines. Multivalent vaccines segment is likely to grow at faster CAGR during the forecast period of 2024-2029. Advancements in recombinant and conjugate vaccine technologies and increased investment by pharmaceutical companies in R&D for next-generation multivalent vaccines has fueled demand for multivalent vaccines.

The US vaccines market is consolidated, with a small number of players competing for market share.  Merck & Co., Inc (US) Pfizer Inc. (US), Emergent (US), Johnson & Johnson Services, Inc (US), Novavax, Inc. (US), Inovio Pharmaceuticals (US), VBI Vaccines (US) and among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the US market.

Related Reports:

US Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com